Health Care [ 5/12 ] | Pharmaceuticals [ 27/73 ]
NASDAQ | Common Stock
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.
It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC.
The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
It also develops SCY-247 to treat systemic fungal diseases.
The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp.
SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | -0.11 Decreased by -1.20 K% | -0.20 Increased by +45.00% |
| Mar 26, 25 | -0.09 Increased by +76.92% | -0.02 Decreased by -350.00% |
| Nov 11, 24 | -0.06 Decreased by -50.00% | -0.07 Increased by +14.29% |
| Aug 8, 24 | -0.30 Decreased by -112.20% | -0.20 Decreased by -50.00% |
| May 8, 24 | 0.01 Increased by +101.41% | -0.20 Increased by +105.00% |
| Feb 7, 24 | -0.39 Decreased by -5.41% | -0.20 Decreased by -95.00% |
| Nov 13, 23 | -0.04 Increased by +93.55% | -0.15 Increased by +73.33% |
| Aug 14, 23 | 2.46 Increased by +893.55% | 1.55 Increased by +58.71% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 257.00 K Decreased by -81.28% | -5.39 M Decreased by -1.41 K% | Decreased by -2.10 K% Decreased by -7.11 K% |
| Dec 31, 24 | 977.00 K Decreased by -83.15% | -4.43 M Increased by +77.37% | Decreased by -453.74% Decreased by -34.30% |
| Sep 30, 24 | 660.00 K Decreased by -62.52% | -2.81 M Decreased by -59.82% | Decreased by -425.45% Decreased by -326.42% |
| Jun 30, 24 | 736.00 K Decreased by -99.44% | -14.46 M Decreased by -111.83% | Decreased by -1.96 K% Decreased by -2.21 K% |
| Mar 31, 24 | 1.37 M Increased by +21.50% | 411.00 K Increased by +101.21% | Increased by +29.93% Increased by +101.00% |
| Dec 31, 23 | 5.80 M Increased by +280.38% | -19.59 M Decreased by -2.39% | Decreased by -337.86% Increased by +73.08% |
| Sep 30, 23 | 1.76 M Increased by +13.10% | -1.76 M Increased by +95.27% | Decreased by -99.77% Increased by +95.82% |
| Jun 30, 23 | 131.45 M Increased by +9.84 K% | 122.26 M Increased by +1.02 K% | Increased by +93.01% Increased by +109.22% |